Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYTH-1: Myocarditis Therapy with IL-1 inhibitor (anakinra)
2024-515472-13-00Phase 2Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Oct 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocarditis comparing Anakinra + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Change in Left Ventricular Ejection Fraction at 2 months. Started Oct 2024; status: completed.
02
Drugs
anakinra
03
Conditions
myocarditis
Beyond the preview
Go deeper on 2024-515472-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515472-13-00.